[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"LensGen, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100467301","clinical-study-to-evaluate-the-lensgen-juvene-intraocular-lens-100467301",false,"NCT05364983","Clinical Study to Evaluate the LensGen® Juvene® Intraocular Lens","A Prospective, Randomized, Controlled, Double-Masked, Phased, Multi-Center Clinical Study to Evaluate the Safety and Efficacy of the LensGen® Juvene® Intraocular Lens","Nirvana","Key Inclusion Criteria:\n\n* Subjects must be 22 years of age or older\n* Able to comprehend and provide written informed consent\n* Willing and able to comply with schedule for follow-up visits\n* Demonstrate sufficient cognitive awareness to comply with examination procedures\n* Other inclusion criteria specified in the protocol may apply.\n\nKey Exclusion Criteria:\n\n* Subjects with clinically significant dry eye syndrome (DES) expected to impact postoperative visual acuity\n* Subjects taking medications that may affect ocular function (including but not limited to mydriatic, cycloplegic and miotic agents; tricyclic antidepressants, phenothiazines, benzodiazepines, first generation antihistamines, and anticholinergic agents)\n* Prior intraocular or corneal surgery (including corneal refractive correction i.e., LASIK, PRK, etc.)\n* Any corneal dystrophy that may affect visual acuity (e.g., keratoconus, pellucid corneal degeneration, etc.)\n* Other exclusion criteria specified in the protocol may apply.",true,"ALL","22 Years",{"count":21,"type":22},56,"ESTIMATED","INTERVENTIONAL",[25],"NA","To assess the safety and effectiveness of the Juvene® IOL for the treatment of aphakia and mitigation of the effects of presbyopia after removal of the natural crystalline lens due to cataract.",[28,29],"Cataract","Presbyopia","NOT_YET_RECRUITING","2023-03-07",{"date":33,"type":34},"2023-03-09","ACTUAL",{"date":36,"type":22},"2023-05",{"date":38,"type":22},"2026-11",{"name":40,"class":41},"LensGen, Inc.","INDUSTRY",""]